Human papilloma virus infection

Related records

Broader conditions (7)

• Disease
• Disease by etiologic mechanism
• Disease of primarily extrinsic mechanism
• Human disease
• Infectious disease
• Primary viral infectious disease
• Viral infectious disease

Narrower conditions (3)

• Anal verrucous carcinoma
• Anogenital human papillomavirus infection
• Buschke Lowenstein tumor

Trials (201)

• A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects
• A Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects.
• A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects
• A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)
• A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers
• A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection
• A Open-label, Drug-Drug Interaction With Maraviroc (DDI)
• A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)
• A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
• A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects
• A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
• A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers
• A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
• A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany
• A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects
• A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects
• A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects
• A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects.
• A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
• A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

Approved drugs (1)

• Human papillomavirus, L1 protein virus like particles

Drugs in development (17)

• Aldesleukin Phase 1
• Balstilimab Phase 2
• Bizalimogene ralaplasmid Phase 1
• Caficrestat Phase 2
• Carrageenan Phase 2
• Doruxapapogene ralaplasmid Phase 1
• Epetirimod Phase 2
• Esepapogene zalarnarepvec Phase 1
• Hepatitis B virus vaccine inactivated Phase 2
• Imiquimod Phase 3
• Infigratinib Phase 2
• Interferon alfa-2B Phase 2
• Ninsipapogene sibarnarepvec Phase 1
• Pembrolizumab Phase 1
• Pexipepimut-S Phase 1
• Tipifarnib Phase 2
• Verpasep caltespen Phase 3

Other linked drugs (2)

• Ellagic acid
• Interferon